A PhII to Evaluate the efficacy, safety and tolerability of AZD5069 in Patients with Uncontrolled Persistant Asthma

Mise à jour : Il y a 5 ans
Référence : EUCTR2012-001869-33

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To determine the efficacy of 3 different doses of AZD5069 compared with placebo on the rate of severe asthma exacerbations over 6 months in adults with uncontrolled persistent asthma, despite treatment with medium to high dose inhaled corticosteroids (≥fluticasone 500 µg or the equivalent daily) and long acting β2 agonists.


Critère d'inclusion

  • Asthma